Skip to main content

Advertisement

Table 2 Changes in clinical parameters after administration of n-3 PUFAs

From: N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study

Parameter Before After P-value
BMI (kg/m2) 28.2 ± 5.4 28.0 ± 5.4 0.700
SBP (mmHg) 141.0 ± 7.6 136.0 ± 11.3 0.113
DBP (mmHg) 74.9 ± 11.0 77.9 ± 11.0 0.334
HbA1c (%) 6.9 ± 0.5 7.1 ± 0.6 0.038
FPG (mg/dL) 132.3 ± 18.7 134.7 ± 25.8 0.664
TC (mg/dL) 171.3 ± 21.5 150.5 ± 16.0 < 0.001
LDL-C (mg/dL) 90.3 ± 17.1 79.4 ± 11.4 0.003
HDL-C (mg/dL) 44.9 ± 9.5 45.5 ± 11.3 0.763
TG (mg/dL) 195.7 ± 49.9 128.7 ± 58.8 < 0.001
EPA/AA 0.30 ± 0.19 1.30 ± 0.30 0.008
DHA/AA 0.75 ± 0.16 1.29 ± 0.32 0.008
AST (IU/L) 21.6 ± 6.0 21.8 ± 5.2 0.828
ALT (IU/L) 24.2 ± 6.0 25.4 ± 7.2 0.977
Cre (mg/dL) 0.81 ± 0.32 0.83 ± 0.36 0.539
  1. Data represent the means ± standard deviation. P-values represent differences observed before and after administration of n-3 PUFAs. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride, AST aspartate aminotransferase, ALT alanine aminotransferase, Cre creatinine